CommercialCoverageMedium impact
Testosterone Enanthate Injection (CPB 1015, reviewed 2026-07-17)
Aetna·Endocrinology, OB-GYN, Pediatrics +4 more·Pharmacy
Effective date
Jul 17, 2026
We identified it
Aug 18, 2026
Summary
Aetna updated its Clinical Policy Bulletin 1015 for testosterone enanthate injection (intramuscular only), effective July 17, 2026. The policy covers four approved indications: hormone-responsive breast cancer, delayed puberty, gender dysphoria (including adolescents meeting specific criteria), and primary/hypogonadotropic hypogonadism. Billing teams must ensure prior authorization requirements are met for covered indications and verify medical necessity documentation, particularly for gender-affirming care and hypogonadism diagnoses.
Action Required
By July 17, 2026: Billing team must update authorization protocols to require prior approval for CPT 96372, 99506, and HCPCS J3121 when billed with approved ICD-10 codes (breast cancer C50.x, E23.0, E29.1, E30.0, or F64.x series). For gender dysphoria claims (F64.0-F64.9), verify prescriber specialization documentation and mental health provider collaboration for members under 18. For hypogonadism claims (E23.0, E29.1), ensure claims include documentation of at least two confirmed low morning testosterone levels. Reject claims for experimental indications: age-related hypogonadism, female sexual dysfunction (F52.0, F52.22), heart failure (I50.1-I50.9), or cognitive decline (R41.81). Update EMR templates and claim submission workflows to include medical necessity checklist. Failure to verify these requirements will result in claim denials.